Our experience spans from small molecules to complex therapeutic proteins like monoclonal antibodies, or vaccines. In addition to these, Accelsiors gained considerable experience in the development of innovative biologics, targeting the epigenetics or molecular immunology mechanisms. Accelsiors designed, managed and monitored multiple Phase I, Phase II, and Phase III clinical trials with involvement of complex clinical, PK/PD, population PK, patients’ reported outcome, immunological, or imaging assessments endpoints.

We have been working in many indications, but our expertise is sepcial in the following therapeutic areas:

Let us support you to manage the complexity of your development program and help to deliver your treatment to the market on-time, on-budget successfully!